These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 621712)

  • 1. [1-Deaminopenicillamine,4-threonine]oxytocin, a potent inhibitor of oxytocin.
    Manning M; Lowbridge J; Seto J; Haldar J; Sawyer WH
    J Med Chem; 1978 Feb; 21(2):179-82. PubMed ID: 621712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [1-Beta-mercapto-beta,beta-pentamethylenepropionic acid]oxytocin, a potent inhibitor of oxytocin.
    Nestor JJ; Ferger MF; du Vigneaud V
    J Med Chem; 1975 Mar; 18(3):284-7. PubMed ID: 1133819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. (4-Phenylalanine)oxytocin, an inhibitor of the antidiuretic effect of 8-arginine-vasopressin.
    Nestor JJ; Ferger MF; Chan WY
    J Med Chem; 1975 Oct; 18(10):1022-4. PubMed ID: 1159680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. (1-Beta-mercaptopropionic acid, 2-(3,5-dibromo-L-tyrosine))oxytocin, a potent inhibitor of oxytocin.
    Lundell EO; Ferger MF
    J Med Chem; 1975 Oct; 18(10):1045-7. PubMed ID: 1159688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and pharmacological properties of [1-L-penicillamine,4-L-leucine]oxytocin.
    Ferger MF; Chan WY
    J Med Chem; 1975 Oct; 18(10):1020-2. PubMed ID: 1159679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthetic antagonists of in vivo responses by the rat uterus to oxytocin.
    Lowbridge J; Manning M; Seto J; Haldar J; Sawyer WH
    J Med Chem; 1979 May; 22(5):565-9. PubMed ID: 458806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and some pharmacological properties of [1-beta-mercapto-beta,beta-diethylpropionic acid,2-(3,5-dibromo-L-tyrosine)]oxytocin.
    Lundell EO; Smith CW; Ferger MF
    J Med Chem; 1975 Dec; 18(12):1262-4. PubMed ID: 1195281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [1-Penicillamine,2-leucine]oxytocin. Synthesis and pharmacological and conformational studies of a potent peptide hormone inhibitor.
    Hruby VJ; Deb KK; Yamamoto DM; Hadley ME; Chan WY
    J Med Chem; 1979 Jan; 22(1):7-12. PubMed ID: 423185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potent antagonists of the antidiuretic responses to arginine-vasopressin based on modifications of [1-(beta-mercapto-beta,beta-cyclopentamethylenepropionic acid),2-D- phenylalanine,4-valine]arginine-vasopressin at position 4.
    Manning M; Olma A; Klis WA; Seto J; Sawyer WH
    J Med Chem; 1983 Nov; 26(11):1607-13. PubMed ID: 6631916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An exploration of the effects of L- and D-tetrahydroisoquinoline-3-carboxylic acid substitutions at positions 2, 3 and 7 in cyclic and linear antagonists of vasopressin and oxytocin and at position 3 in arginine vasopressin.
    Manning M; Cheng LL; Stoev S; Bankowski K; Przybyiski J; Klis WA; Sawyer WH; Wo NC; Chan WY
    J Pept Sci; 1995; 1(1):66-79. PubMed ID: 9222985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design of potent antagonists of the vasopressor response to arginine-vasopressin.
    Bankowski K; Manning M; Haldar J; Sawyer WH
    J Med Chem; 1978 Sep; 21(9):850-3. PubMed ID: 722751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Solid-phase synthesis of 16 potent (selective and nonselective) in vivo antagonists of oxytocin.
    Manning M; Kruszynski M; Bankowski K; Olma A; Lammek B; Cheng LL; Klis WA; Seto J; Haldar J; Sawyer WH
    J Med Chem; 1989 Feb; 32(2):382-91. PubMed ID: 2913298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and some pharmacological properties of [1-(L-2-hydroxy-3-mercaptopropanoic acid), 4-threonine]oxytocin (hydroxy [4-thr]oxytocin), a peptide with strikingly high oxytocic potency and of [1-(L-2-hydroxy-3-mercaptopropanoic acid)]oxytocin (hydroxy-oxytocin).
    Manning M; Lowbridge J; Sawyer WH; Haldar J
    J Med Chem; 1976 Mar; 19(3):376-80. PubMed ID: 943546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and some pharmacological properties of two new antagonists of oxytocin.
    Rekowski P; Melin P; Lammek B
    Pol J Pharmacol Pharm; 1987; 39(3):303-7. PubMed ID: 3438212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antagonists of oxytocin featuring replacement with modified beta-mercaptopropionic acids at position 1.
    Flouret G; Majewski T; Balaspiri L; Brieher W; Mahan K; Chaloin O; Wilson L; Slaninová J
    J Pept Sci; 2002 Jul; 8(7):314-26. PubMed ID: 12148781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and some pharmacological properties of five analogs of oxytocin having L-homocysteine in position 6.
    Smith CW; Ferger MF
    J Med Chem; 1976 Feb; 19(2):250-4. PubMed ID: 1249804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design of oxytocin antagonists, which are more selective than atosiban.
    Manning M; Stoev S; Cheng LL; Wo NC; Chan WY
    J Pept Sci; 2001 Sep; 7(9):449-65. PubMed ID: 11587184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthetic antagonists of the myometrial response to vasopressin and oxytocin.
    Melin P; Trojnar J; Johansson B; Vilhardt H; Akerlund M
    J Endocrinol; 1986 Oct; 111(1):125-31. PubMed ID: 3783079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Some biological properties of an "irreversible" antagonist of neurohypophyseal hormones, deamino-[Phe(4-BrCH2CONH)2]-oxytocin, and its isosteric analogue, deamino-[Phe(4-CH3CH2CONH)2]-oxytocin.
    Pliska V; Marbach P
    Eur J Pharmacol; 1978 Jun; 49(3):213-22. PubMed ID: 658139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The design of effective in vivo antagonists of rat uterus and milk ejection responses to oxytocin.
    Sawyer WH; Haldar J; Gazis D; Seto J; Bankowski K; Lowbridge J; Turan A; Manning M
    Endocrinology; 1980 Jan; 106(1):81-91. PubMed ID: 7349976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.